Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Squizzato, Alessandro ^a   Romualdi, E ^b   Middeldorp, S ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO; TICLOPIDINE;

CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; EMBASE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FAILURE; LONG TERM CARE; LOW DRUG DOSE; MANTEL HAENSZEL TEST; MEDLINE; MORTALITY; NEUTROPENIA; POLYCYTHEMIA VERA; QUANTITATIVE ANALYSIS; RASH; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTE; THROMBOCYTHEMIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 44949094483     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006503.pub2     Document Type: Review

References (26)

1. ECLAP 2004 {published data only} *Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al.Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine 2004;350:114-24.
2. GISP 1997 {published data only} *Gruppo Italiano Studio Policitemia Vera (GISP). Low-dose aspirin in polycythaemia vera: a pilot study. British Journal of Haematology 1997;97:453-6.
3. Finelli 1991 Finelli C, Palareti G, Poggi M, Torricelli P, Vianelli N, Fiacchini M, et al.Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors. Acta Haematologica 1991;85:113-8.
4. Tartaglia 1986 Tartaglia AP, Goldberg JD, Berck PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Seminars in Hematology 1986;23:172-6.
5. Ania 1994 Ania BJ, Suman VJ, Sobell JL, et al.Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. American Journal of Hematology 1994;47:89-93.
6. ATC 2002 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 2002;324:71-86.
7. Campbell 2005 Campbell PJ, Green AR. Management of polycythaemia vera and essential thrombocythaemia. Hematology / the Education Program of the American Society of Hematology 2005;1:201-8.
8. Cortelazzo 1990 Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythaemia. Journal of Clinical Oncology 1990;8:556-62.
9. Cortelazzo 1995 Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al.Hydroxyurea for patients with essential thrombocythaemia and high risk of thrombosis. New England Journal of Medicine 1995;332:1132-6.
10. Egger 1997 Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315:629-34.
11. Finazzi 2005 Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al.Acute leukemia in polycythaemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-70.
12. GISP 1995 Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Annals of Internal Medicine 1995;123:656-64.
13. Handbook 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd, 2006.
14. Harrison 2005 Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al.Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine 2005;353(1):33-45.
15. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327:557-60.
16. Landolfi 1992 Landolfi R, Ciabattoni G, Pugliese F, et al.Increased thromboxane biosynthesis in patients with polycythaemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992;80:1965-71.
17. Landolfi 1997 Landolfi R, Marchioli R. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomised trial. Seminars in Thrombosis and Haemostasis 1997;23:473-8.
18. Lau 2006 Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. British Medical Journal 2006;333:597-600.
19. Maclure 1987 Maclure M, Willett WC. Misinterpretation and misuse of the kappa statistic. American Journal of Epidemiology 1987;126:161-9.
20. Marchioli 2005 Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al.Vascular and neoplastic risk in a large cohort of patients with polycythaemia vera. Journal of Clinical Oncology 2005;23:2224-32.
21. Mesa 1999 Mesa RA, Silverstein MN, Jacobsen SJ, et al.Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. American Journal of Hematology 1999;61:10-15.
22. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
23. Passamonti 2004 Passamonti F, Rumi E, Pungolino E, et al.Life expectancy and prognostic factors for survival in patients with polycythaemia vera and essential thrombocythaemia. American Journal of Medicine 2004;117:755-61.
24. RevMan 2003 The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagan: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
25. Rocca 1995 Rocca B, Ciabattoni G, Tartaglione R, et al.Increased thromboxane biosynthesis in essential thrombocythaemia. Thrombosis and Haemostasis 1995;74:1225-30.
26. WHO 2002 Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.